Study #2023-0018
Phase 1/2, multi-center, open-label study to evaluate the safety, tolerability, and preliminary anti-tumor activity of TNG462 as a single agent and in combination in patients with MTAP-deleted advanced or metastatic solid tumors.
MD Anderson Study Status
Enrolling
Treatment Agent
TNG462, Pembrolizumab
Description
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 225 participants.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Locally Advanced Solid Tumor
Study phase:
Physician name:
Jordi Rodon Ahnert
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-855-946-3759
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.